Browse by funding committee
Cancer Research UK's Research Funding Committee structure is designed to ensure excellence in peer review and provides a balance of strategic and response mode funding streams. Each Committee has its own remit and range of awards:
The Clinical Trials Awards and Advisory Committee (CTAAC) reviews and funds cancer clinical trials. CTAAC is responsible for the review, funding and management of awards for phase I and II studies testing aspects of feasibility or tolerability and/or efficacy, larger phase II and phase III therapeutic clinical trials and sample collections.
The New Agents Committee (NAC) selects new anti-cancer treatments for early clinical trials. The NAC is interested in proposals for scientifically-driven trials of novel unregistered anti-cancer agents.
The Population Research Committee (PRC) is responsible for the oversight, development, review, funding and management of a portfolio of awards for research Programmes and Projects Grants in population science.
The Science Committee has superseded four of Cancer Research UK’s funding committees in the area of basic, translational and drug discovery. Applications that would have been within the remit of the Biological Sciences Committee; the Clinical and Translational Research Committee, the Discovery Committee and the Biomarkers & Imaging Discovery & Development Committee are now considered by the Science Committee.
The Tobacco Advisory Group (TAG) is a funding and policy-setting committee focussing on several key priority tobacco policy areas. Through the TAG, Cancer Research UK aims to complement its policy and campaigning work by funding related projects and research, as well as other work of national and international significance.
The Training and Career Development Board reviews, funds and manages the portfolio and budget of Cancer Research UK's Fellowship and Bursary Awards. It also plays a guiding role in the training of postdoctoral scientists.